- Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
- Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
- Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
- Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
- Acrivon Therapeutics Announces $130 Million Private Placement Financing
- Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
- Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
- Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
More ▼
Key statistics
On Thursday, Acrivon Therapeutics Inc (ACRV:NMQ) closed at 7.34, 130.09% above the 52 week low of 3.19 set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.44 |
---|---|
High | 7.54 |
Low | 7.23 |
Bid | 7.25 |
Offer | 7.99 |
Previous close | 7.39 |
Average volume | 107.11k |
---|---|
Shares outstanding | 30.88m |
Free float | 18.44m |
P/E (TTM) | -- |
Market cap | 238.37m USD |
EPS (TTM) | -2.88 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼